PMID- 34626443
OWN - NLM
STAT- MEDLINE
DCOM- 20220331
LR  - 20220401
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Linking)
VI  - 37
IP  - 8
DP  - 2021 Nov
TI  - The new dual gastric inhibitory peptide/glucagon-like peptide 1 agonist 
      tirzepatide in type 2 diabetes: Is the future bright?
PG  - e3503
LID - 10.1002/dmrr.3503 [doi]
AB  - Tirzepatide is a dual gastric inhibitory peptide/glucagon-like peptide 1 
      (GIP/GLP-1) receptor agonist formulated as a synthetic linear peptide, based on 
      the native GIP sequence. It has a prolonged half-life of 5 days, which enables 
      once-weekly dosing. Studies have hitherto demonstrated its superiority in 
      achieving optimal glycaemic control and body weight management, as compared with 
      various agents used in the treatment of type 2 diabetes mellitus (T2DM), 
      including GLP-1 receptor agonists. Thus, it is expected to enrich our therapeutic 
      armamentarium in T2DM. However, further experience, notably longer follow-up data 
      and information on cardiovascular effects, is still needed.
CI  - (c) 2021 John Wiley & Sons Ltd.
FAU - Papachristou, Stella
AU  - Papachristou S
AD  - Second Department of Internal Medicine, Diabetes Centre, Democritus University of 
      Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.
FAU - Popovic, Djordje S
AU  - Popovic DS
AUID- ORCID: 0000-0002-2763-1326
AD  - Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Center of 
      Vojvodina, Novi Sad, Serbia.
AD  - Medical Faculty, University of Novi Sad, Novi Sad, Serbia.
FAU - Papanas, Nikolaos
AU  - Papanas N
AUID- ORCID: 0000-0002-7320-785X
AD  - Second Department of Internal Medicine, Diabetes Centre, Democritus University of 
      Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.
LA  - eng
PT  - Journal Article
DEP - 20211015
PL  - England
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 59392-49-3 (Gastric Inhibitory Polypeptide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - OYN3CCI6QE (tirzepatide)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Gastric Inhibitory Polypeptide/pharmacology
MH  - *Glucagon-Like Peptide 1/pharmacology
MH  - Glucagon-Like Peptide-1 Receptor/agonists
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/therapeutic use
OTO - NOTNLM
OT  - antidiabetic therapy
OT  - gastric inhibitory peptide
OT  - glucagon-like peptide 1
OT  - tirzepatide
OT  - type 2 diabetes
EDAT- 2021/10/10 06:00
MHDA- 2022/04/01 06:00
CRDT- 2021/10/09 12:14
PHST- 2021/10/10 06:00 [pubmed]
PHST- 2022/04/01 06:00 [medline]
PHST- 2021/10/09 12:14 [entrez]
AID - 10.1002/dmrr.3503 [doi]
PST - ppublish
SO  - Diabetes Metab Res Rev. 2021 Nov;37(8):e3503. doi: 10.1002/dmrr.3503. Epub 2021 
      Oct 15.